Biocon Q4FY26 Total Income Rs 4,569 Cr

Biocon reported Q4FY26 total income of Rs 4,569 crore, with operating revenue up 10% YoY excluding one-time lenalidomide sales.
EBITDA for Q4 stood at Rs 1,073 crore, up 29% YoY on adjusted basis, with net profit before exceptional items at Rs 179 crore.
The board recommended a final dividend of Re. 0.50 per share and announced several new director appointments effective August 2026.
Biosimilars remained the growth driver with 12% YoY revenue increase to Rs 2,756 crore in Q4, while generics grew 13% and CRDMO grew 2%.